A post hoc analysis of KidneyIntelX and cardiorenal outcomes in diabetic kidney disease
Author(s)
Type
Journal Article
Abstract
Key Points
KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.
Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.
These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.
KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.
Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.
These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.
Date Issued
2022-09-29
Date Acceptance
2022-05-12
Citation
Kidney360, 2022, 3 (9), pp.1599-1602
ISSN
2641-7650
Publisher
Wolters Kluwer
Start Page
1599
End Page
1602
Journal / Book Title
Kidney360
Volume
3
Issue
9
Copyright Statement
Copyright © 2022 by the American Society of Nephrology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
License URL
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000864688600018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
Life Sciences & Biomedicine
Science & Technology
Urology & Nephrology
Publication Status
Published
Date Publish Online
2022-09-29